KEYNOTE-061: Phase 3 study of pembrolizumab vs paclitaxel for previously treated advanced gastric or gastroesophageal junction (G/GEJ) cancer

被引：0

作者：

Shitara, K. ^{[1
]}

Ozguroglu, M. ^{[2
]}

Bang, Y. J. ^{[3
]}

Di Bartolomeo, M. ^{[4
]}

Mandala, M. ^{[5
]}

Ryu, M. H. ^{[6
]}

Fornaro, L. ^{[7
]}

Olesinski, T. ^{[8
]}

Caglevic, C. ^{[9
]}

Chung, H. ^{[10
]}

Muro, K. ^{[11
]}

Gokkurt, E. ^{[12
]}

Mansoor, W. ^{[13
]}

McDermott, R. ^{[14
]}

Schacham-Shmueli, E. ^{[15
]}

Chen, X. ^{[16
]}

Kang, S. P. ^{[16
]}

Mayo, C. ^{[16
]}

Ohtsu, A. ^{[1
]}

Fuchs, C. ^{[17
]}

机构：

[1] Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan

[2] Istanbul Univ, Cerrahpasa Sch Med, Istanbul, Turkey

[3] Seoul Natl Univ, Coll Med, Seoul, South Korea

[4] Fdn IRCCS Ist Nazl Tumori, Milan, Italy

[5] Papa Giovanni XXIII Hosp, Bergamo, Italy

[6] Asan Med Ctr, Seoul, South Korea

[7] Azienda Osped Univ Pisana, Pisa, Italy

[8] Maria Sklodowska Curie Mem Canc Ctr, Warsaw, Poland

[9] Inst Oncol Fdn Arturo Lopez Perez, Santiago, Chile

[10] Yonsei Univ, Coll Med, Yonsei Canc Ctr, Seoul, South Korea

[11] Aichi Canc Ctr Hosp, Nagoya, Aichi, Japan

[12] HOPE, Hamburg, Germany

[13] Christie Hosp NHS Fdn Trust, Manchester, Lancs, England

[14] Adelaide & Meath Hosp, Dublin, Ireland

[15] Sheba Med Ctr, Ramat Gan, Israel

[16] Merck & Co Inc, Kenilworth, NJ USA

[17] Yale Canc Ctr, New Haven, CT USA

来源：

ANNALS OF ONCOLOGY | 2018年 / 29卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

LBA - 005

引用

页数：1

共 50 条

[1] KEYNOTE-061: pembrolizumab vs paclitaxel for previously treated advanced gastric or gastroesophageal junction cancer
Shitara, Kohei
Muro, Kei
Satoh, Taroh
Tamura, Takao
Chin, Keisho
Machida, Nozomu
Hara, Hiroki
Hironaka, Shuichi
Sugimoto, Naotoshi
Mayo, Carlos
Han, Rong
Shiratori, Shinichi
Ohtsu, Atsushi
ANNALS OF ONCOLOGY, 2018, 29 : 49 - 49
[2] Pembrolizumab (pembro) vs paclitaxel (PTX) for previously treated advanced gastric or gastroesophageal junction (G/GEJ) cancer: Phase 3 KEYNOTE-061 trial.
Fuchs, Charles S.
Ozguroglu, Mustafa
Bang, Yung-Jue
Di Bartolomeo, Maria
Mandala, Mario
Ryu, Min-Hee
Fornaro, Lorenzo
Olesinski, Tomasz
Caglevic, Christian
Chung, Hyun Cheol
Muro, Kei
Goekkurt, Eray
Mansoor, Wasat
McDermott, Raymond S.
Shacham-Shmueli, Einat
Chen, Xinqun
Kang, S. Peter
Mayo, Carlos Alberto
Ohtsu, Atsushi
Shitara, Kohei
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[3] Pembrolizumab versus paclitaxel as second-line therapy for advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: Phase 3 KEYNOTE-061 study.
Ohtsu, Atsushi
Tabernero, Josep
Bang, Yung-Jue
Fuchs, Charles S.
Sun, Linda
Wang, Zhen
Csiki, Ildiko
Koshiji, Minori
Van Cutsem, Eric
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[4] Pembrolizumab (MK-3475) versus paclitaxel as second-line therapy for advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: Phase 3 KEYNOTE-061 study.
Ohtsu, Atsushi
Tabernero, Josep
Bang, Yung-Jue
Fuchs, Charles S.
Sun, Linda
Wang, Zhen
Csiki, Ildiko
Koshiji, Minori
Van Cutsem, Eric
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
[5] Pembrolizumab versus paclitaxel for previously treated PD-L1-positive advanced gastric or gastroesophageal junction cancer: 2-year update of the randomized phase 3 KEYNOTE-061 trial
Fuchs, Charles S.
Ozguroglu, Mustafa
Bang, Yung-Jue
Di Bartolomeo, Maria
Mandala, Mario
Ryu, Min-Hee
Fornaro, Lorenzo
Olesinski, Tomasz
Caglevic, Christian
Chung, Hyun C.
Muro, Kei
Van Cutsem, Eric
Elme, Anneli
Thuss-Patience, Peter
Chau, Ian
Ohtsu, Atsushi
Bhagia, Pooja
Wang, Anran
Shih, Chie-Schin
Shitara, Kohei
GASTRIC CANCER, 2022, 25 (01) : 197 - 206
[6] Pembrolizumab versus paclitaxel for previously treated PD-L1-positive advanced gastric or gastroesophageal junction cancer: 2-year update of the randomized phase 3 KEYNOTE-061 trial
Charles S. Fuchs
Mustafa Özgüroğlu
Yung-Jue Bang
Maria Di Bartolomeo
Mario Mandala
Min-Hee Ryu
Lorenzo Fornaro
Tomasz Olesinski
Christian Caglevic
Hyun C. Chung
Kei Muro
Eric Van Cutsem
Anneli Elme
Peter Thuss-Patience
Ian Chau
Atsushi Ohtsu
Pooja Bhagia
Anran Wang
Chie-Schin Shih
Kohei Shitara
Gastric Cancer, 2022, 25 : 197 - 206
[7] Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial
Shitara, Kohei
Ozguroglu, Mustafa
Bang, Yung-Jue
Di Bartolomeo, Maria
Mandala, Mario
Ryu, Min-Hee
Fornaro, Lorenzo
Olesinski, Tomasz
Caglevic, Christian
Chung, Hyun C.
Muro, Kei
Goekkurt, Eray
Mansoor, Wasat
McDermott, Raymond S.
Shacham-Shmueli, Einat
Chen, Xinqun
Mayo, Carlos
Kang, S. Peter
Ohtsu, Atsushi
Fuchs, Charles S.
LANCET, 2018, 392 (10142): : 123 - 133
[8] Pembrolizumab (MK-3475) versus paclitaxel as second-line therapy for advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: Randomized, open-label, phase 3 KEYNOTE-061 study
Ohtsu, A.
Tabernero, J.
Bang, Y. -J.
Fuchs, C.
Sun, L.
Wang, Z.
Csiki, I.
Koshiji, M.
Van Cutsem, E.
ANNALS OF ONCOLOGY, 2015, 26
[9] Pembrolizumab versus paclitaxel for previously treated patients with PD-L1-positive advanced gastric or gastroesophageal junction cancer (GC): Update from the phase III KEYNOTE-061 trial.
Fuchs, Charles S.
Ozguroglu, Mustafa
Bang, Yung-Jue
Di Bartolomeo, Maria
Mandala, Mario
Ryu, Min-hee
Fornaro, Lorenzo
Olesinski, Tomasz
Caglevic, Christian
Chung, Hyun Cheol
Muro, Kei
Van Cutsem, Eric
Elme, Anneli
Thuss-Patience, Peter C.
Chau, Ian
Ohtsu, Atsushi
Bhagia, Pooja
Wang, Anran
Shih, Chie-Schin
Shitara, Kohei
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[10] KEYNOTE-061: Response to subsequent therapy following second-line pembrolizumab or paclitaxel in patients with advanced gastric or gastroesophageal junction adenocarcinoma
Yoon, H.
Fuchs, C.
Ozguroglu, M.
Bang, Y.
Di Bartolomeo, M.
Mandala, M.
Ryu, M.
Fornaro, L.
Olesinski, T.
Caglevic, C.
Chung, H.
Muro, K.
Van Cutsem, E.
Elme, A.
Thuss-Patience, P.
Chau, I.
Ohtsu, A.
Wang, A.
Bhagia, P.
Lin, J.
Shih, C.
Shitara, K.
ANNALS OF ONCOLOGY, 2020, 31 : S236 - S236

← 1 2 3 4 5 →